Search

Your search keyword '"van de Wakker, Simonides I."' showing total 14 results
Start Over Author "van de Wakker, Simonides I."
14 results on '"van de Wakker, Simonides I."'

1. Inter-laboratory multiplex bead-based surface protein profiling of MSC-derived EV preparations identifies MSC-EV surface marker signatures

Author

Nguyen, Vivian V.T., Welsh, Joshua A., Tertel, Tobias, Choo, Andre, van de Wakker, Simonides I., Defourny, Kyra A.Y., Giebel, Bernd, Vader, Pieter, Padmanabhan, Jayanthi, Lim, Sai Kiang, Nolte-'t Hoen, Esther N.M., Verhaar, Marianne C., Bostancioglu, R. Beklem, Zickler, Antje M., Hong, Jia Mei, Jones, Jennifer C., EL Andaloussi, Samir, van Balkom, Bas W.M., Görgens, André, Nguyen, Vivian V.T., Welsh, Joshua A., Tertel, Tobias, Choo, Andre, van de Wakker, Simonides I., Defourny, Kyra A.Y., Giebel, Bernd, Vader, Pieter, Padmanabhan, Jayanthi, Lim, Sai Kiang, Nolte-'t Hoen, Esther N.M., Verhaar, Marianne C., Bostancioglu, R. Beklem, Zickler, Antje M., Hong, Jia Mei, Jones, Jennifer C., EL Andaloussi, Samir, van Balkom, Bas W.M., and Görgens, André

Abstract

Mesenchymal stromal cells (MSCs) are promising regenerative therapeutics that primarily exert their effects through secreted extracellular vesicles (EVs). These EVs – being small and non-living – are easier to handle and possess advantages over cellular products. Consequently, the therapeutic potential of MSC-EVs is increasingly investigated. However, due to variations in MSC-EV manufacturing strategies, MSC-EV products should be considered as highly diverse. Moreover, the diverse array of EV characterisation technologies used for MSC-EV characterisation further complicates reliable interlaboratory comparisons of published data. Consequently, this study aimed to establish a common method that can easily be used by various MSC-EV researchers to characterise MSC-EV preparations to facilitate interlaboratory comparisons. To this end, we conducted a comprehensive inter-laboratory assessment using a novel multiplex bead-based EV flow cytometry assay panel. This assessment involved 11 different MSC-EV products from five laboratories with varying MSC sources, culture conditions, and EV preparation methods. Through this assay panel covering a range of mostly MSC-related markers, we identified a set of cell surface markers consistently positive (CD44, CD73 and CD105) or negative (CD11b, CD45 and CD197) on EVs of all explored MSC-EV preparations. Hierarchical clustering analysis revealed distinct surface marker profiles associated with specific preparation processes and laboratory conditions. We propose CD73, CD105 and CD44 as robust positive markers for minimally identifying MSC-derived EVs and CD11b, CD14, CD19, CD45 and CD79 as reliable negative markers. Additionally, we highlight the influence of culture medium components, particularly human platelet lysate, on EV surface marker profiles, underscoring the influence of culture conditions on resulting EV products. This standardisable approach for MSC-EV surface marker profiling offers a tool for routine characterisation

Published
2024

2. Inter-laboratory multiplex bead-based surface protein profiling of MSC-derived EV preparations identifies MSC-EV surface marker signatures

Author

Cardiologie, CDL Staf Research, CDL Cluster Onderzoek en Onderwijs, Circulatory Health, Zorgeenheid Vaatchirurgie Medisch, UMC Utrecht Holding, Nefro Vasculaire Geneeskunde, Regenerative Medicine and Stem Cells, MS Nefrologie, Nguyen, Vivian V.T., Welsh, Joshua A., Tertel, Tobias, Choo, Andre, van de Wakker, Simonides I., Defourny, Kyra A.Y., Giebel, Bernd, Vader, Pieter, Padmanabhan, Jayanthi, Lim, Sai Kiang, Nolte-'t Hoen, Esther N.M., Verhaar, Marianne C., Bostancioglu, R. Beklem, Zickler, Antje M., Hong, Jia Mei, Jones, Jennifer C., EL Andaloussi, Samir, van Balkom, Bas W.M., Görgens, André, Cardiologie, CDL Staf Research, CDL Cluster Onderzoek en Onderwijs, Circulatory Health, Zorgeenheid Vaatchirurgie Medisch, UMC Utrecht Holding, Nefro Vasculaire Geneeskunde, Regenerative Medicine and Stem Cells, MS Nefrologie, Nguyen, Vivian V.T., Welsh, Joshua A., Tertel, Tobias, Choo, Andre, van de Wakker, Simonides I., Defourny, Kyra A.Y., Giebel, Bernd, Vader, Pieter, Padmanabhan, Jayanthi, Lim, Sai Kiang, Nolte-'t Hoen, Esther N.M., Verhaar, Marianne C., Bostancioglu, R. Beklem, Zickler, Antje M., Hong, Jia Mei, Jones, Jennifer C., EL Andaloussi, Samir, van Balkom, Bas W.M., and Görgens, André

Published
2024

4. Inter‐laboratory multiplex bead‐based surface protein profiling of MSC‐derived EV preparations identifies MSC‐EV surface marker signatures.

Author

Nguyen, Vivian V. T., Welsh, Joshua A., Tertel, Tobias, Choo, Andre, van de Wakker, Simonides I., Defourny, Kyra A. Y., Giebel, Bernd, Vader, Pieter, Padmanabhan, Jayanthi, Lim, Sai Kiang, Nolte‐'t Hoen, Esther N. M., Verhaar, Marianne C., Bostancioglu, R. Beklem, Zickler, Antje M., Hong, Jia Mei, Jones, Jennifer C., EL Andaloussi, Samir, van Balkom, Bas W. M., and Görgens, André

Subjects
EXTRACELLULAR vesicles, STROMAL cells, MANUFACTURED products, HIERARCHICAL clustering (Cluster analysis), CD19 antigen, LABORATORIES
Abstract

Mesenchymal stromal cells (MSCs) are promising regenerative therapeutics that primarily exert their effects through secreted extracellular vesicles (EVs). These EVs – being small and non‐living – are easier to handle and possess advantages over cellular products. Consequently, the therapeutic potential of MSC‐EVs is increasingly investigated. However, due to variations in MSC‐EV manufacturing strategies, MSC‐EV products should be considered as highly diverse. Moreover, the diverse array of EV characterisation technologies used for MSC‐EV characterisation further complicates reliable interlaboratory comparisons of published data. Consequently, this study aimed to establish a common method that can easily be used by various MSC‐EV researchers to characterise MSC‐EV preparations to facilitate interlaboratory comparisons. To this end, we conducted a comprehensive inter‐laboratory assessment using a novel multiplex bead‐based EV flow cytometry assay panel. This assessment involved 11 different MSC‐EV products from five laboratories with varying MSC sources, culture conditions, and EV preparation methods. Through this assay panel covering a range of mostly MSC‐related markers, we identified a set of cell surface markers consistently positive (CD44, CD73 and CD105) or negative (CD11b, CD45 and CD197) on EVs of all explored MSC‐EV preparations. Hierarchical clustering analysis revealed distinct surface marker profiles associated with specific preparation processes and laboratory conditions. We propose CD73, CD105 and CD44 as robust positive markers for minimally identifying MSC‐derived EVs and CD11b, CD14, CD19, CD45 and CD79 as reliable negative markers. Additionally, we highlight the influence of culture medium components, particularly human platelet lysate, on EV surface marker profiles, underscoring the influence of culture conditions on resulting EV products. This standardisable approach for MSC‐EV surface marker profiling offers a tool for routine characterisation of manufactured EV products in pre‐clinical and clinical research, enhances the quality control of MSC‐EV preparations, and hopefully paves the way for higher consistency and reproducibility in the emerging therapeutic MSC‐EV field. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Identification of storage conditions stabilizing extracellular vesicles preparations

Author

Görgens, André, primary, Corso, Giulia, additional, Hagey, Daniel W., additional, Jawad Wiklander, Rim, additional, Gustafsson, Manuela O., additional, Felldin, Ulrika, additional, Lee, Yi, additional, Bostancioglu, R. Beklem, additional, Sork, Helena, additional, Liang, Xiuming, additional, Zheng, Wenyi, additional, Mohammad, Dara K., additional, van de Wakker, Simonides I., additional, Vader, Pieter, additional, Zickler, Antje M., additional, Mamand, Doste R., additional, Ma, Li, additional, Holme, Margaret N., additional, Stevens, Molly M., additional, Wiklander, Oscar P. B., additional, and EL Andaloussi, Samir, additional

Published
2022
Full Text
View/download PDF

7. Functional siRNA Delivery by Extracellular Vesicle-Liposome Hybrid Nanoparticles

Author

Evers, Martijn, van de Wakker, Simonides I, de Groot, Ellis M, de Jong, Olivier G., Francois, J.J.J.M., Seinen, Cor, Sluijter, Joost P G, Schiffelers, Raymond, Vader, Pieter, Evers, Martijn, van de Wakker, Simonides I, de Groot, Ellis M, de Jong, Olivier G., Francois, J.J.J.M., Seinen, Cor, Sluijter, Joost P G, Schiffelers, Raymond, and Vader, Pieter

Abstract

The therapeutic use of RNA interference is limited by the inability of siRNA molecules to reach their site of action, the cytosol of target cells. Lipid nanoparticles, including liposomes, are commonly employed as siRNA carrier systems to overcome this hurdle, although their widespread use remains limited due to a lack of delivery efficiency. More recently, nature's own carriers of RNA, extracellular vesicles (EVs), are increasingly being considered as alternative siRNA delivery vehicles due to their intrinsic properties. However, they are difficult to load with exogenous cargo. Here, EV-liposome hybrid nanoparticles (hybrids) are prepared and evaluated as an alternative delivery system combining properties of both liposomes and EVs. It is shown that hybrids are spherical particles encapsulating siRNA, contain EV-surface makers, and functionally deliver siRNA to different cell types. The functional behavior of hybrids, in terms of cellular uptake, toxicity, and gene-silencing efficacy, is altered as compared to liposomes and varies among recipient cell types. Moreover, hybrids produced with cardiac progenitor cell (CPC) derived-EVs retain functional properties attributed to CPC-EVs such as activation of endothelial signaling and migration. To conclude, hybrids combine benefits of both synthetic and biological drug delivery systems and might serve as future therapeutic carriers of siRNA.

Published
2022

8. Functional siRNA Delivery by Extracellular Vesicle-Liposome Hybrid Nanoparticles

Author

Afd Pharmaceutics, Pharmaceutics, Evers, Martijn, van de Wakker, Simonides I, de Groot, Ellis M, de Jong, Olivier G., Francois, J.J.J.M., Seinen, Cor, Sluijter, Joost P G, Schiffelers, Raymond, Vader, Pieter, Afd Pharmaceutics, Pharmaceutics, Evers, Martijn, van de Wakker, Simonides I, de Groot, Ellis M, de Jong, Olivier G., Francois, J.J.J.M., Seinen, Cor, Sluijter, Joost P G, Schiffelers, Raymond, and Vader, Pieter

Published
2022

9. Identification of storage conditions stabilizing extracellular vesicles preparations

Author

Experimentele Afd. Cardiologie 2, Cardiologie, CDL Cluster Onderzoek en Onderwijs, Circulatory Health, Görgens, André, Corso, Giulia, Hagey, Daniel W., Jawad Wiklander, Rim, Gustafsson, Manuela O., Felldin, Ulrika, Lee, Yi, Bostancioglu, R. Beklem, Sork, Helena, Liang, Xiuming, Zheng, Wenyi, Mohammad, Dara K., van de Wakker, Simonides I., Vader, Pieter, Zickler, Antje M., Mamand, Doste R., Ma, Li, Holme, Margaret N., Stevens, Molly M., Wiklander, Oscar P.B., EL Andaloussi, Samir, Experimentele Afd. Cardiologie 2, Cardiologie, CDL Cluster Onderzoek en Onderwijs, Circulatory Health, Görgens, André, Corso, Giulia, Hagey, Daniel W., Jawad Wiklander, Rim, Gustafsson, Manuela O., Felldin, Ulrika, Lee, Yi, Bostancioglu, R. Beklem, Sork, Helena, Liang, Xiuming, Zheng, Wenyi, Mohammad, Dara K., van de Wakker, Simonides I., Vader, Pieter, Zickler, Antje M., Mamand, Doste R., Ma, Li, Holme, Margaret N., Stevens, Molly M., Wiklander, Oscar P.B., and EL Andaloussi, Samir

Published
2022

10. Functional siRNA Delivery by Extracellular Vesicle–Liposome Hybrid Nanoparticles

Author

CDL Nanomedicine, Experimentele Afd. Cardiologie 2, Centraal Diagnostisch Laboratorium, Onderzoek Vrouw Hart & Vaatziekten, Onderzoek Cardiovasculair Reg. Med., Circulatory Health, Regenerative Medicine and Stem Cells, CDL Cluster Onderzoek en Onderwijs, Cancer, Evers, Martijn J.W., van de Wakker, Simonides I., de Groot, Ellis M., de Jong, Olivier G., Gitz-François, Jerney J.J., Seinen, Cor S., Sluijter, Joost P.G., Schiffelers, Raymond M., Vader, Pieter, CDL Nanomedicine, Experimentele Afd. Cardiologie 2, Centraal Diagnostisch Laboratorium, Onderzoek Vrouw Hart & Vaatziekten, Onderzoek Cardiovasculair Reg. Med., Circulatory Health, Regenerative Medicine and Stem Cells, CDL Cluster Onderzoek en Onderwijs, Cancer, Evers, Martijn J.W., van de Wakker, Simonides I., de Groot, Ellis M., de Jong, Olivier G., Gitz-François, Jerney J.J., Seinen, Cor S., Sluijter, Joost P.G., Schiffelers, Raymond M., and Vader, Pieter

Published
2022

13. New drug-strategies to tackle viral-host interactions for the treatment of influenza virus infections

Author

van de Wakker, Simonides I, Fischer, Marcel J E, Oosting, Ronald S, van de Wakker, Simonides I, Fischer, Marcel J E, and Oosting, Ronald S

Abstract

The influenza virus (IV) is a highly contagious virus causing seasonal global outbreaks affecting annually up to 20% of the world's population and leading to 250,000-500,000 deaths worldwide. Current vaccines have variable effectiveness, and, in particular during a pandemic outbreak, they are probably not available in the amounts needed to protect the world population. Therefore we need effective small molecule drugs to combat an IV infection and that can be produced, in case of pandemic, rapidly and in large quantities. Unfortunately, natural occurring IV becomes more and more resistant to current anti-IV drugs. And thus, there is an urgent need for development of alternative agents with new mechanisms of action. This review provides an overview of the pharmacology and effectiveness of new anti-IV agents, focusing on inhibition mechanisms directed against virus-host interactions.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results